Omakase

About Omakase

This author has not yet filled in any details.
So far Omakase has created 92 blog entries.

Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated
Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated

Its now available the 4th edition of EDS Journal cotaining several articles about latest actuality. To highlight, there is an interesting entry about how to assess clinical benefit in order to accelerate access of innovative drugs where multidisciplinar experts have participated

Omakase2020-11-17T18:07:49+00:00November 17th, 2020|News & Events|

Register and check the whole edition on the following link: https://economiadela [...]

The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Foundation on behalf of ASCO are now available on its website
The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Foundation on behalf of ASCO are now available on its website

The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Foundation on behalf of ASCO are now available on its website

Omakase2020-11-16T15:45:24+00:00November 16th, 2020|News & Events|

The recordings of the 2nd Oncology Quality Care Symposium developed by ECO Found [...]

Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.
Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.

Today at 1.30pm, Dr. Badía participates as an expert in the session “Cost, value and clinical benefit in the Oncology setting” to talk about MCDA for evaluating and positioning cancer treatments.

Omakase2020-11-13T12:11:31+00:00November 13th, 2020|News & Events|

Check more information about the symposium and join on streaming on the followin [...]

Dr. Badia, CEO Omakase Consulting, will participate in a conference meeting at the 2nd Oncology Quality Care Symposium (November, 12-13th) to present “MCDA for evaluating and positioning cancer treatments”
Dr. Badia, CEO Omakase Consulting, will participate in a conference meeting at the 2nd Oncology Quality Care Symposium (November, 12-13th) to present “MCDA for evaluating and positioning cancer treatments”

Dr. Badia, CEO Omakase Consulting, will participate in a conference meeting at the 2nd Oncology Quality Care Symposium (November, 12-13th) to present “MCDA for evaluating and positioning cancer treatments”

Omakase2020-11-11T09:37:21+00:00November 11th, 2020|News & Events|

On November 12-13th takes place the second Oncology Quality Care Symposium. The [...]

Proud to be co-authors of a poster published in the official journal of the LXII National Congress of the Spanish Society of Haematology and Hemotherapy on the determination of the challenges and opportunities associated with platelet transfusion in the management of CLD-associated severe thrombocytopenia
Proud to be co-authors of a poster published in the official journal of the LXII National Congress of the Spanish Society of Haematology and Hemotherapy on the determination of the challenges and opportunities associated with platelet transfusion in the management of CLD-associated severe thrombocytopenia

Proud to be co-authors of a poster published in the official journal of the LXII National Congress of the Spanish Society of Haematology and Hemotherapy on the determination of the challenges and opportunities associated with platelet transfusion in the management of CLD-associated severe thrombocytopenia

Omakase2020-11-06T11:26:02+00:00November 6th, 2020|News & Events|

Orgullosos de ser coautores de un póster publicado en la revista oficial del LXI [...]

The September 2020 summary of P&R decisions from the Spanish Interministerial Medicinal Products Pricing Committee (CIPM) is now translated and available to download in English.
The September 2020 summary of P&R decisions from the Spanish Interministerial Medicinal Products Pricing Committee (CIPM) is now translated and available to download in English.

The September 2020 summary of P&R decisions from the Spanish Interministerial Medicinal Products Pricing Committee (CIPM) is now translated and available to download in English.

Omakase2020-10-29T15:14:25+00:00October 29th, 2020|News & Events|

Download the translated version here: Summary P&R CIPM Decisions _ September [...]

The September 2020 summary of P&R decisions in Spain is now available for downloading

Omakase2020-10-29T15:10:17+00:00October 29th, 2020|P&R Committee Resolutions (CIMP)|

The September 2020 summary of P&R decisions from the Spanish Interministeria [...]

Adding up methodologies like GENESIS and Multi Criteria Decision Analysis (MCDA), a way to explore in the near future to improve drugs evaluation in Spain.
Adding up methodologies like GENESIS and Multi Criteria Decision Analysis (MCDA), a way to explore in the near future to improve drugs evaluation in Spain.

Adding up methodologies like GENESIS and Multi Criteria Decision Analysis (MCDA), a way to explore in the near future to improve drugs evaluation in Spain.

Omakase2020-10-22T09:45:07+00:00October 22nd, 2020|News & Events|

Yesterday, Dr. Badía, Dr. Poveda and Dr. Martínez shared their experiences on th [...]

Yesterday, in the 65th SEFH virtual Congress, a panel of 3 experts from Orphar-SEFH group and Dr. Badia from Omakase Consulting shared their experiences about Horizon Scanning reports talking about how to develop it and use it for anticipating new drugs coming to Spain.
Yesterday, in the 65th SEFH virtual Congress, a panel of 3 experts from Orphar-SEFH group and Dr. Badia from Omakase Consulting shared their experiences about Horizon Scanning reports talking about how to develop it and use it for anticipating new drugs coming to Spain.

Yesterday, in the 65th SEFH virtual Congress, a panel of 3 experts from Orphar-SEFH group and Dr. Badia from Omakase Consulting shared their experiences about Horizon Scanning reports talking about how to develop it and use it for anticipating new drugs coming to Spain.

Omakase2020-10-21T09:18:21+00:00October 21st, 2020|News & Events|

Conference focused on the Horizon Scanning of orphan drugs report developed by O [...]

This week, from 20th to 22nd October, takes place the 65th National Congress of Spanish Society of Hospital Pharmacy, 100% online for the first time. This edition will include several chats about timeliness topics such as experiences about Horizon Scanning of Orphan Drugs and MCDA methodology that will be shared by Dr. Badía, CEO Omakase Consulting.
This week, from 20th to 22nd October, takes place the 65th National Congress of Spanish Society of Hospital Pharmacy, 100% online for the first time. This edition will include several chats about timeliness topics such as experiences about Horizon Scanning of Orphan Drugs and MCDA methodology that will be shared by Dr. Badía, CEO Omakase Consulting.

This week, from 20th to 22nd October, takes place the 65th National Congress of Spanish Society of Hospital Pharmacy, 100% online for the first time. This edition will include several chats about timeliness topics such as experiences about Horizon Scanning of Orphan Drugs and MCDA methodology that will be shared by Dr. Badía, CEO Omakase Consulting.

Omakase2020-10-19T16:23:34+00:00October 19th, 2020|News & Events|

Check the full program in the following link: https://65congreso.sefh.es/program [...]

Load More Posts

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies